Purpose: This study aimed at comparing the efficacy of chemiluminescence and toluidine blue in detecting oral dysplasias and malignancies in at an early stage. Material and methods: A total of 26 patients who had potentially malignant lesions were included in the current study. All lesions were examined using Vizilite TM chemiluminescence followed by painting them with toluidine blue biostain. Then, all lesions were biopsied to be the gold standard for assessing both the chemiluminescence and the toluidine blue. Results: The current study showed low sensitivity, but high specificity and positive predictive value of TB (57.15%, 60%, and 85.71% respectively). On contrary, were the results of Vizilite (85.71%, 25%, and 57.14% on order). Conclusion: Although biopsy is the gold standard to detect dysplasia, toluidine blue and Vizilite were valuable non-invasive and rapid adjunct techniques that aided in the clinical detection and screening of dysplasia. They might have a special value in the screening for the existence of new lesions in patients with previous oral malignancies.